

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/053604

## A. CLASSIFICATION OF SUBJECT MATTER

C12N15/11 A61K31/7125 A61K31/04 A61K31/166 A61K31/52  
A61K31/7048 A61P35/00 C07K14/495 A61K38/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C12N A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, WPI Data, PAJ, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ARTEAGA C L ET AL: "REVERSAL OF TAMOXIFEN RESISTANCE OF HUMAN BREAST CARCINOMAS IN VIVO BY NEUTRALIZING ANTIBODIES TO TRANSFORMING GROWTH FACTOR-BETA" JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 91, no. 1, 6 January 1999 (1999-01-06), pages 46-53, XP000940473 ISSN: 0027-8874	1,3,7-9, 11-16
Y	the whole document	1-17
Y	WO 94/25588 A (BIOGNOSTIK GES ; BOGDAHN ULRICH (DE); BRYSCH WOLFGANG (DE); SCHLINGENS) 10 November 1994 (1994-11-10) cited in the application the whole document	1-17

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

3 August 2005

Date of mailing of the international search report

30.01.2006

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Andres, S

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/053604

## C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WOJTOWICZ-PRAGA SLAWOMIR: "Reversal of tumor-induced immunosuppression by TGF-beta inhibitors." INVESTIGATIONAL NEW DRUGS, vol. 21, no. 1, February 2003 (2003-02), pages 21-32, XP008035079 ISSN: 0167-6997 cited in the application the whole document	1-17
A	YU D ET AL: "HYBRID OLIGONUCLEOTIDES: SYNTHESIS, BIOPHYSICAL PROPERTIES STABILITY STUDIES, AND BIOLOGICAL ACTIVITY" BIOORGANIC & MEDICINAL CHEMISTRY, vol. 4, no. 10, 1996, pages 1685-1692, XP000644792 ISSN: 0968-0896	
A	RUBENSTEIN MARVIN ET AL: "Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol." MEDICAL ONCOLOGY (TOTOWA), vol. 20, no. 1, 2003, pages 29-35, XP008035083 ISSN: 1357-0560 the whole document	
A	WO 99/63975 A (BIOGNOSTIK GES ; BRYSCH WOLFGANG (DE); SCHLINGENSIEPEN KARL HERMANN (D) 16 December 1999 (1999-12-16) cited in the application	
A	WO 01/68146 A (BIOGNOSTIK GES ; SCHLINGENSIEPEN KARL HERMANN (DE); SCHLINGENSIEPEN RE) 20 September 2001 (2001-09-20) cited in the application	
P,X	WO 2004/005552 A (MONIA BRETT P ; DOBIE KENNETH W (US); FREIER SUSAN M (US); ISIS PHARMA) 15 January 2004 (2004-01-15) page 54 - page 55 page 79; example 5 page 91 - page 100; examples 15,16	1-3,5-16

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/053604

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9425588	A	10-11-1994	AT 211762 T	15-01-2002
			AT 235549 T	15-04-2003
			AU 6794594 A	21-11-1994
			DE 69429617 D1	14-02-2002
			DE 69429617 T2	22-08-2002
			DE 69432375 D1	30-04-2003
			DE 69432375 T2	12-02-2004
			JP 3555952 B2	18-08-2004
			JP 8509370 T	08-10-1996
			JP 3600831 B2	15-12-2004
			JP 2004024264 A	29-01-2004
			US 6455689 B1	24-09-2002
WO 9963975	A	16-12-1999	AT 274923 T	15-09-2004
			AU 5154999 A	30-12-1999
			CA 2334960 A1	16-12-1999
			DE 69919869 D1	07-10-2004
			DE 69919869 T2	29-09-2005
			ES 2226414 T3	16-03-2005
			JP 2002517434 T	18-06-2002
WO 0168146	A	20-09-2001	AT 304858 T	15-10-2005
			AU 6010901 A	24-09-2001
			EP 1133988 A1	19-09-2001
			JP 2003526684 T	09-09-2003
			US 2003186906 A1	02-10-2003
WO 2004005552	A	15-01-2004	AU 2003281327 A1	23-01-2004
			US 2004006030 A1	08-01-2004